A B S T R A C T The proliferative response ofT lymphocytes cultured with autologous non-T lymphocytes is known as the autologous mixed lymphocyte reaction (MLR). This reaction can be demonstrated reproducibly in healthy individuals and has been shown to generate specific cytotoxic T cells, as well as T cells that regulate antibody synthesis and cell-mediated immunity. In this study, we demonstrate that the autologous MLR is impaired or absent in most patients with Hodgkin's disease regardless of age, sex, pathologic stage, or histologic classification. In 64 patients, the mean autologous MLR was 3,084+ 1,878 cpm compared to 16 ,552+6,532 in 29 healthy donors. A defect in autologous MLR was observed in newly diagnosed patients before the initiation of therapy, but was also found in patients without evidence of recurrent disease up to 15 yr after treatment.
These findings could not be explained by abnormal kinetics or poor viability of stimulator or responder cells. The possibility that suppressor cells are responsible for the reduction of T cell autoreactivity was examined by comparing the autologous MLR of a healthy HLA-identical sibling in the presence and absence of T or non-T cells of an affected sibling. No inhibitory effects were observed. Similarly, substitution of patient plasma for pooled AB serum failed to inhibit the autologous responses of normal donors. Increasing the number of responder T cells in the culture or removing adherent cells from the stimulator population enhanced autoreactivity in some patients, indicating that the defect is not absolute. In two families, T cells of healthy HLA-A, B, and DR-identical siblings of patients responded normally to the non-T cells of their affected siblings, whereas patients' T cells failed to respond both to their own stimulator cells and those INTRODUCTION The immunologic status of patients with Hodgkin's disease has been a topic of intensive investigation for the past two decades. Although antibody responses appear to be unimpaired (1, 2) , patients frequently exhibit defects of T cell-mediated immune functions manifested by diminished delayed hypersensitivity responses (3) (4) (5) (6) (7) , impaired ability to reject skin allografts (8) (9) (10) , and decreased resistance to certain types of infection (11) (12) . Several in vitro functions of peripheral blood T cells have been shown to be impaired, including the blastogenic response to soluble antigens (13) (14) (15) , alloantigens (16, 17) , and plant lectins (2, (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Some ofthese defects may be explained by the presence of suppressor monocytes (17, (28) (29) (30) and suppressor T cells (29, 31) . Although these abnormalities are of variable magnitude and are not diagnostic of Hodgkin's disease, their frequent occurrence in patients with this malignancy suggests that a defect of cell-mediated immunity may play a role in the pathogenesis of the disease.
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Alternatively, B cells were separated from T cells on the basis ofbinding to plastic petri dishes coated with anti-human Ig (46) . In this technique 3 x 107 PBML in 3 ml 5% FCS-PBS were incubated for 70 min at room temperature in a 100 x 25 mm polystyrene petri dish (Lab-Tek Div.) coated with F(ab)2' goat anti-human Ig (N. L. Cappel Laboratories Inc., Cochranville, Pa.). Unbound cells were decanted, and the dish was gently flushed five times with 10 ml of 1% FCS-PBS. Bound cells were recovered by filling the dish with 25 
RESULTS
Autologous and allogeneic MLR in normal volunteers and patients. T cells from normal volunteers and patients with Hodgkin's disease were cultured with either irradiated autologous non-T cells or irradiated allogeneic PBML, and proliferation was measured after 1 wk (Fig. 1) . The mean autologous MLR of29 normal subjects was Fig. 2 . There was no evidence of accelerated or delayed responses in any of 10 patients tested (including 3 with untreated disease), indicating that the defective autologous MLR of these patients cannot be explained by altered kinetics.
Effects of increasing the number of autologous responder and stimulator cells. Studies were performed to determine whether the diminished autologous MLR in patients could be augmented by increasing the number of stimulator or responder cells. As shown in Fig. 3A , the responses of four healthy volunteers increased as the number of responder cells was increased. The responses ofthree offour Hodgkin's patients (Fig. 3B ) also increased as a function of the responder cell number, but remained consistently determine whether the impaired autologous MLR was due to a defect of responder cells, stimulator cells, or both, two patients in remission and their healthy HLAidentical siblings were studied. In these studies, T lymphocytes from a patient, an HLA-A, B, DR-identical sibling, and an unrelated healthy volunteer were cultured with non-T lymphocytes from each ofthese three subjects. As shown in Table III (47) , but this procedure did not increase responses by T cells in the autologous MLR. We further examined this question by separating T cells from non-T cells using a method other than rosetting with sheep erythrocytes. In five patients T cells were separated from non-T cells on the basis of binding to plastic petri dishes coated with anti-Ig and were then tested in the autologous MLR. The results (Table IV) indicate that with either positive selection or negative selection for T cells, patient T cells mounted diminished responses in the autologous MLR.
In an effort to remove any membrane-bound blocking nodal irradiation (TNI), which has significant longterm effects on the functions of peripheral blood lymphocytes (48) . Indeed, TNI prolongs the survival of histoincompatible organ allografts in rats (49), suppresses experimental autoimmune disease in mice (50) , and is currently under investigation as an immunotherapeutic modality in man. A few patients in this study who were tested 10 yr or more after treatment had normal autologous MLR reactivity, suggesting that recovery of this response may eventually occur. Determination of the precise effects of radiation therapy on the autologous MLR require studies of patients with disorders other than Hodgkin's disease who have normal autologous MLR before treatment. In this regard, patients with intractible rheumatoid arthritis are currently undergoing a clinical trial of TNI at Stanford University. Studies of these patients before and after treatment indicate that TNI acutely inhibits both the autologous and allogeneic MLR, but a longer follow-up period is required to determine the duration of these effects.2 A number of potential explanations for the impaired autologous MLR in Hodgkin's disease, such as increased sensitivity of stimulator cells to X-irradiation, poor viability of stimulator or responder cells, dissociation ofthymidine uptake from blast transformation, and accelerated or delayed kinetics of response, were ruled out experimentally. Increases in the number of responder T cells or depletion of adherent cells from the non-T cell stimulator population enhanced the autologous MLR in some patients, indicating that these patients are not totally devoid of autoreactive cells. However, these maneuvers failed to restore responses to normal levels and, therefore, alternative explanations were sought for the defect.
The nature of the defect in two patients who had been treated previously was clarified by performing reciprocal mixing experiments between patients and their healthy HLA-identical siblings. A similar approach has been used by other investigators to demonstrate that the diminished autologous MLR in patients with systemic lupus erythematosus is in some cases a consequence of defective stimulator cells (51) and in other cases a consequence of defective responder cells (52) . A defect of autologous stimulator cells has been described in patients with mononucleosis (41) and chronic lymphocytic leukemia (53, 54 
